When researchers at the University of Leeds put semaglutide to the test against visceral fat specifically — not just total body weight — the results were striking. A 2023 analysis published in Diabetes Care found that participants using semaglutide lost disproportionately more visceral adipose tissue (VAT) compared to subcutaneous fat, even when controlling for overall weight loss. That distinction matters enormously. Visceral fat — the metabolically active fat packed around your liver, pancreas, and intestines — is the fat most closely linked to insulin resistance, cardiovascular disease, type 2 diabetes, and systemic inflammation. Losing it isn’t just about fitting into smaller pants. It’s about changing your internal metabolic environment from the ground up.
GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have emerged as the most discussed pharmaceutical tools for fat loss in decades. But the conversation around them too often focuses on the scale — how much total weight comes off — rather than asking the more important question: what kind of fat are you losing, and from where? The emerging body of research is answering that question in compelling ways, and the answers have implications for how men think about metabolic health regardless of whether they’re using these medications or not.
Why Visceral Fat Is the Real Enemy
Not all fat behaves the same way. Subcutaneous fat — the soft layer under your skin — is largely inert from a metabolic standpoint. It has its own problems at high levels, but it doesn’t secrete the same volume of inflammatory cytokines and free fatty acids that visceral fat does. Visceral adipose tissue is biologically active in a way that makes it uniquely dangerous. Research published in Circulation established decades ago that VAT accumulation is an independent predictor of cardiovascular events, even in men who aren’t clinically obese by BMI standards. A man can be a “normal” weight and still carry dangerous levels of visceral fat — a phenotype researchers now call TOFI, or “thin outside, fat inside.”
Visceral fat also drives what many metabolic researchers consider the central pathology behind modern chronic disease: ectopic lipid deposition. When VAT expands beyond its natural capacity, it begins to dump fat into the liver (contributing to non-alcoholic fatty liver disease), the pancreas (impairing insulin secretion), and skeletal muscle (reducing insulin sensitivity). This is the domino effect that transforms excess abdominal fat into full-blown metabolic syndrome. Reducing visceral fat isn’t a cosmetic goal — it’s a clinical one.
What GLP-1 Medications Do to Visceral Fat Specifically
The GLP-1 receptor agonist class was originally developed for blood sugar control, but the fat loss data — particularly the visceral fat data — has reframed how the medical community thinks about these drugs. A randomized controlled trial published in The Lancet examining semaglutide 2.4mg in adults with obesity found average weight reductions of 14.9% over 68 weeks. But the breakdown of where that fat came from is where the science gets particularly relevant. Imaging studies using MRI and DEXA have consistently shown that GLP-1 agonists preferentially reduce visceral fat at a rate that exceeds what you’d expect from caloric restriction alone.
A 2023 study in Obesity using MRI-quantified fat compartments found that semaglutide-treated subjects experienced a roughly 40% reduction in visceral fat volume alongside a 14% reduction in subcutaneous fat — a ratio that strongly favors the more dangerous depot. The mechanism behind this preferential effect isn’t fully understood, but researchers believe it involves GLP-1’s influence on hepatic lipid metabolism, its modulation of the autonomic nervous system’s regulation of adipose tissue, and its downstream effects on insulin sensitivity that make visceral fat cells more responsive to lipolytic signals.
Tirzepatide, which acts on both GLP-1 and GIP receptors, appears to push this effect even further. Data from the SURMOUNT-1 trial showed tirzepatide at the highest dose (15mg) producing average weight loss of 22.5% — with imaging substudies confirming substantial visceral fat reduction. For context, that level of visceral fat loss would typically require years of disciplined lifestyle intervention. The pharmacological lever is powerful.
There is, however, a critical caveat that any man on or considering these medications needs to understand: weight loss without resistance training risks significant lean mass loss alongside fat loss. An analysis in Diabetes, Obesity and Metabolism found that roughly 25-39% of weight lost on semaglutide could be attributed to lean mass in some cohorts. That’s a metabolic problem — losing muscle reduces resting metabolic rate, impairs glucose uptake, and sets the stage for fat regain. This is why resistance training isn’t optional for GLP-1 users. It’s the primary defense against the muscle loss that can accompany rapid pharmaceutical weight loss.
Lifestyle Interventions That Target Visceral Fat by the Same Mechanisms
For men not using GLP-1 medications, the research on visceral fat reduction through lifestyle is both robust and actionable. The same metabolic pathways these drugs influence — insulin sensitivity, hepatic fat clearance, inflammatory cytokine production — respond to targeted dietary and exercise interventions. A landmark JAMA study comparing aerobic exercise, resistance training, and their combination found that aerobic exercise was the most efficient modality for reducing visceral fat specifically, even when total weight loss was similar across groups. The combination group, however, showed the most favorable overall body composition outcomes — losing visceral fat while preserving or gaining lean mass.
Dietary approaches matter too, and the research points toward carbohydrate quality and insulin load as key variables. A study in Annals of Internal Medicine found that a low-carbohydrate diet produced greater visceral fat loss than a low-fat diet of equal calories over six months — likely because of the direct effect carbohydrate restriction has on lowering insulin, the hormone that most strongly promotes visceral fat storage. This doesn’t mean every man needs to go keto, but it does suggest that reducing refined carbohydrates and sugar should be a priority for anyone serious about attacking visceral fat specifically.
Sleep is the underappreciated variable in this equation. Research from the University of Chicago demonstrated that sleep restriction — even just two weeks of sleeping 5.5 hours rather than 8.5 — significantly blunted fat loss and shifted the composition of weight lost away from fat and toward lean mass. The hormonal disruption caused by poor sleep (elevated cortisol, suppressed growth hormone, increased ghrelin) creates the same internal environment that makes visceral fat difficult to reduce even when diet and exercise are dialed in.
What This Means For You
Whether you’re using a GLP-1 medication or building your metabolic health purely through training and nutrition, the target is the same: reduce visceral adipose tissue, preserve lean mass, and improve insulin sensitivity. The pharmacological tools have gotten remarkably powerful, and the research shows they work — but they work best when stacked with resistance training, a diet that controls insulin load, adequate sleep, and consistent aerobic activity. For men using GLP-1 agonists, the visceral fat reduction data is genuinely exciting. For men pursuing the same goal through lifestyle alone, the same data confirms what you already suspected: the fat around your organs is the most important fat to move, and the tools to move it — lifting, running, sleeping, and eating well — are already in your hands.